Decadron (dexamethasone) / Merck (MSD) - LARVOL DELTA

NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=3 | Active, not recruiting | Sponsor: Elvira Umyarova | Recruiting ➔ Active, not recruiting | N=30 ➔ 3 | Trial completion date: Aug 2025 ➔ Jan 2026 | Trial primary completion date: Aug 2025 ➔ Jan 2026

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Equity and Resource Allocation: The Case for Allogeneic Transplant in Emergency Medicaid Patients (ASH 2023) - "He began maintenance BCNU/cytoxan, then several cycles 6-MP/MTX/vincristine. On day +554 after diagnosis, he relapsed and started decitabine/venetoclax, then decadron + dasatinib, then MVP, followed by 3 cycles of inotuzumab...As his condition worsened he was put on ponatinib, then asciminib before expiring on day +940...On day +447 he started blinatumomab + IT MTX + nilotinib...The patient underwent leukapheresis and started HiDAC + mitoxantrone + etoposide + dasatinib...Likewise, many undocumented adults are the parents of US citizen minors who would benefit economically from their survival. For consideration we will explore cost analysis to further elucidate the potential benefit of allowing coverage of HSCT."

HEOR • Medicaid • Reimbursement • US reimbursement • Acute Myelogenous Leukemia • Bone Marrow Transplantation • CNS Disorders • Epilepsy • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases • Transplantation • ABL1 • BCR

ALL Backbone in AYAs (clinicaltrials.gov) - P2 | N=67 | Not yet recruiting | Sponsor: Dana-Farber Cancer Institute

New P2 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial (clinicaltrials.gov) - P4 | N=94 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open • Allergy • Hematological Malignancies • Multiple Myeloma • Oncology

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial (clinicaltrials.gov) - P1/2 | N=10 | Active, not recruiting | Sponsor: University of Southern California | Recruiting ➔ Active, not recruiting | N=42 ➔ 10

Enrollment change • Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease (clinicaltrials.gov) - P2 | N=28 | Suspended | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Suspended

Trial suspension • Hematological Malignancies • Multiple Myeloma • Oncology

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=2 | Terminated | Sponsor: Adriana Rossi | N=36 ➔ 2 | Trial completion date: Jun 2028 ➔ Apr 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2028 ➔ Apr 2025; Study closure is due to insufficient supply of study drug.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - P3 | N=452 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

SINE: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=52 | Completed | Sponsor: University of Chicago | Recruiting ➔ Completed | N=100 ➔ 52 | Trial completion date: Dec 2026 ➔ Oct 2025 | Trial primary completion date: Jul 2026 ➔ Oct 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • CRBN

Hepatic Cry for Help: A Case of HSOS (Hepatic Sinusoidal Obstructive Syndrome) After Brentuximab and Dacarbazine Chemotherapy (ACG 2025) - "We present a case of HSOS in the setting of recent Brentuximab and Dacarbazine infusion for the management of advanced Hodgkin Lymphoma.Case Description/ A 19-year-old male with a history of advanced Mixed Cellularity (Classic) Hodgkin Lymphoma who previously experienced hepatotoxicity secondary to Nivolumab was transitioned to BV-AVD (Brentuximab/Doxorubicin/Vinblastine/Dacarbazine) infusions...Defibrotide was initiated after MICU admission...Fortunately, after a course of IV Decadron and supportive management, his condition steadily improved...It is difficult to clearly delineate which chemotherapeutic agent caused HSOS in this patient although Dacarbazine is favored. This case shows the importance of an early radiologic diagnosis to raise clinical suspicion for HSOS in order to initiate proper treatment to optimize patient outcomes.Figure: Axial image showing marked periportal edema in addition to diffuse heterogeneous liver parenchyma (nutmeg liver) characteristic of..."

Clinical • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Liver Failure • Lymphoma

THE INVASIVE SPECIES (CHEST 2025) - "CASE PRESENTATION: A 62-year-old female with past medical history of Lynch syndrome, right ureteral cancer on Keytruda, chronic bilateral hydronephrosis with chronic indwelling ureteral stents, chronic foley, colonic adenocarcinoma post-proctocolectomy, and CKD Stage 4 presented with progressive hematuria, suprapubic discomfort, dizziness, and fatigue...Bone marrow biopsy demonstrated HLH and she was started on Decadron via the HLH-90 protocol, and voriconazole after ureteral fragment pathology resulted for aspergillus... Secondary HLH is a severe inflammatory disorder with high mortality, requiring strong clinical suspicion."

Chronic Kidney Disease • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Dyslipidemia • Fatigue • Genetic Disorders • Genito-urinary Cancer • Hemophagocytic lymphohistiocytosis • Hypertriglyceridemia • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Rare Diseases • Respiratory Diseases • Solid Tumor • Thrombocytopenia • IL2RA • ISG20

NCI-2018-02830: Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P2 | N=40 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Oct 2025 ➔ Oct 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P2 | N=23 | Terminated | Sponsor: University of California, San Diego | Completed ➔ Terminated; The trial met its primary endpoint.

Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

QUAD: A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=17 | Active, not recruiting | Sponsor: Hackensack Meridian Health | Trial completion date: Sep 2025 ➔ Jul 2026 | Trial primary completion date: Sep 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov) - P1/2 | N=49 | Active, not recruiting | Sponsor: Mayo Clinic | Trial primary completion date: May 2027 ➔ Mar 2026

Trial primary completion date • Breast Cancer • Hematological Malignancies • Multiple Myeloma • Oncology

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov) - P1 | N=24 | Suspended | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Suspended

Trial suspension • Amyloidosis • Multiple Myeloma • BCL2

SWOG S0777: Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (clinicaltrials.gov) - P3 | N=525 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - P3 | N=5949 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Central Nervous System Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • ETV6 • KMT2A • RUNX1

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - P2 | N=53 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2028 ➔ Mar 2029 | Trial primary completion date: Apr 2028 ➔ Mar 2029

Enrollment open • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics

Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure (clinicaltrials.gov) - P=N/A | N=68 | Not yet recruiting | Sponsor: University of North Carolina, Chapel Hill

New trial • Genetic Disorders • Obesity

A RARE CASE OF DIFFUSE ALVEOLAR HEMORRHAGE INDUCED BY HUMAN METAPNEUMOVIRUS: A NOVEL APPROACH TO TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN (IVIG) (CHEST 2025) - "His respiratory status gradually improved, allowing discharge on room air with a Decadron taper Intravenous immunoglobulin (IVIG) is a pooled blood product containing polyclonal immunoglobulin G (IgG) antibodies that modulate the immune system through multiple molecular mechanisms... This case demonstrates the rare link between HMPV and DAH. IVIG shows potential in modulating immune response in treatment of DAH."

Clinical • ANCA Vasculitis • Cardiovascular • Cough • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Musculoskeletal Diseases • Orthopedics • Pulmonary Disease • Respiratory Diseases • Rheumatology • Systemic Lupus Erythematosus • Vasculitis • IL6 • TNFA

WORSENING LOWER EXTREMITY WEAKNESS AFTER STEROID USE: A CASE REPORT HIGHLIGHTING EXCELLENT RESPONSE TO PLASMAPHARESIS IN GUILLAIN BARRÉ (CHEST 2025) - "They recommended starting Decadron for treatment... Early recognition of Guillain-Barré Syndrome (GBS) and its variants is crucial for initiating timely and appropriate treatment, such as intravenous immunoglobulin (IVIG) and/or plasma exchange (PLEX). GBS is a life-threatening condition, with a high mortality risk due to complications like respiratory failure, pneumonia, autonomic dysfunction, and cardiac arrest. In this case, the use of corticosteroids was associated with an increased risk of adverse outcomes, highlighting the potential dangers of steroid treatment in GBS patients."

Case report • Clinical • Cardiovascular • Immunology • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics • Pneumonia • Respiratory Diseases

A HIDDEN FISTULA: A CASE OF COVID-19 CLOAKING AN UNUSUAL ENDOCARDITIS FINDING (CHEST 2025) - "On admission his work-up was consistent with COVID-19 Pneumonia he initially responded well to IV Decadron and Remdesivir, and quickly returned to room air. However, he remained persistently positive for methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia during his hospital course despite appropriate antibiotic treatment with Cefazolin.Chest x-ray (CXR), computed tomography of the abdomen and pelvis (CT A/P), and transthoracic echocardiogram (TTE), failed to identify an infectious source, complicating the clinical picture... Endocarditis can develop as a complication in patients with recent COVID-19, leading to significant morbidity and mortality. Clinicians should be vigilant for this possibility, especially given the overlapping symptoms and the potential for severe outcomes"

Clinical • Cardiovascular • Chronic Kidney Disease • Infectious Disease • Nephrology • Novel Coronavirus Disease • Pneumonia • Renal Disease • Respiratory Diseases

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis (clinicaltrials.gov) - P1/2 | N=10 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial primary completion date: Aug 2025 ➔ Nov 2025

Trial primary completion date • Hemophagocytic lymphohistiocytosis • Immunology • Rare Diseases • IL2 • IL2RA • ISG20 • LAMP1 • PRF1 • RAB27A • STXBP2 • UNC13D • XIAP

AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=669 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology